转自：新华财经 一直以来，青岛将生物制造作为未来产业培育的重中之重，系统谋划、精准发力，特别是《青岛市合成 生物创新发展行动方案（2025-2027年）》的正式印发，为产业发展绘制了清晰"路线图"、制定了有 力"保障网"，推动产业发展迈出坚实步伐。以青岛琅琊台集团等为代表的骨干企业，在海洋生物资源开 发、微生物发酵技术等领域积淀深厚，发展生物制造未来产业既有基础、更有优势、更具潜力。 据了解，青岛琅琊台集团将海洋微生物技术赋能白酒酿造，打造"中国海派白酒"；依托衣康酸及其衍生 物研产销基地，坚定向合成生物制造高端领域迈进；建成海洋微藻、海洋活性肽等研发生产基地，推动 海洋生物资源的高值化开发与新质生产力转化。目前，青岛琅琊台集团已成功建设"国家认定企业技术 中心""国家级工业设计中心""中国轻工业海洋资源挖掘与产品创制工程技术中心"等八大"国字号"研发 平台，先后承担多项国家重点研发计划，并获得国家科技进步奖二等奖，在技术研发、产业转化与规模 生产等方面取得扎实成效。 青岛琅琊台集团相关负责人表示："未来，集团将坚持创新驱动，进一步深化与科研机构的产学研合 作，构建可持续的创新源泉；加速推动研发成果产业化，促 ...

Core Viewpoint - The transfer of state-owned equity in the Qingdao Langyatai Group to the Qingdao West Coast Health Industry Development Group represents a significant move in the reform of state-owned enterprises and the promotion of industrial clustering in the West Coast New Area [2][3] Group 1: Equity Transfer Details - On June 11, Qingdao Haikong Group announced the transfer of its 41.79% stake in Langyatai Group to the Health Industry Group without compensation [2][5] - Following the transfer, the Health Industry Group will become the new controlling shareholder of Langyatai Group, while the employee shareholding ratio remains unchanged [5] Group 2: Company Background - Langyatai Group, originally established as Qingdao First Brewery in 1958, has transformed from a single liquor producer to a diversified industrial group, becoming one of the top 100 enterprises in China's liquor industry [4] - As of the end of 2024, Langyatai Group has total assets of 2.559 billion yuan and net assets of 769 million yuan, with an operating income of 541 million yuan and a net profit of 18.5854 million yuan [5] Group 3: Health Industry Group Overview - The Health Industry Group, established in 2018, is a new force within the Qingdao state-owned asset system, with a registered capital of 500 million yuan [7] - By the end of 2024, its asset scale reached 9.387 billion yuan, which is 3.7 times that of Langyatai Group, but it only achieved a net profit of 6 million yuan and has total liabilities of 5.946 billion yuan [8] Group 4: Strategic Implications - The equity transfer is not merely an asset maneuver but a strategic move to enhance resource synergy between the Health Industry Group and Langyatai Group, particularly in the biomedicine sector [10][13] - Langyatai Group's expertise in marine biotechnology and the Health Industry Group's medical resources could create a closed-loop ecosystem for research, production, and application in the health industry [14]